Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deforolimus maintenance therapy in metastatic soft tissue or bone sarcoma
ACTRN12608000214336Phase 3Recruiting
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Sep 2007
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in soft tissue sarcoma (STS) and bone cancer comparing Ridaforolimus maintenance with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Sep 2007; status: recruiting.
02
Drugs
ridaforolimus
03
Conditions
soft tissue sarcoma (STS)bone cancer
Beyond the preview
Go deeper on ACTRN12608000214336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000214336.